Flow cytometry solutions provider Cytek Biosciences (Fremont, CA) has now shipped 100 of its advanced flow cytometry systems. First introduced in June 2017, the company's systems give scientists the ability to obtain deeper biological insights from a single sample.
A technique used to detect and measure the physical and chemical characteristics of a population of cells or particles, flow cytometry has become an invaluable tool in research and clinical studies with various biomedical and therapeutic applications, such as investigating the role of the body's immune system in fighting cancer, diagnosing leukemia and lymphoma, and detecting minimal residual disease in organ transplant patients. While the benefits offered by flow cytometry are well known, adoption has lagged because of its cost-prohibitive, workflow-intensive nature.
"The sale of our one hundredth system in less than 18 months is an indication that our technology is hitting the sweet spot for price and performance," says Wenbin Jiang, CEO of Cytek Biosciences. "We plan to keep this momentum going by continuing to extend and accelerate our reach and capabilities."
For more information, please visit www.cytekbio.com.